microRNA as prognostic and diagnostic markers in malignant melanoma.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024417

Enrollment

Registered

2021-08-11

Start date

2021-04-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43.9

Interventions

Group 1: Peripheral blood serum of patients with malignant melanoma will be collected during routine blood sampling and analyzed with in situ hybridization and quantitative realtime PCR to detect miRN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed malignant melanoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
progression free survival	—

Countries

Germany

Contacts

Public ContactCord Sunderkötter

Universitätsklinikum Halle (Saale)

cord.sunderkoetter@uk-halle.de03455573988

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026